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Familial exudative vitreoretinopathy (FEVR) is an inherited blinding disorder of the retinal vascular system. Auto-
somal dominant FEVR is genetically heterogeneous, but its principal locus, EVR1, is on chromosome 11q13-q23.
The gene encoding the Wnt receptor frizzled-4 (FZD4) was recently reported to be the EVR1 gene, but our mutation
screen revealed fewer patients harboring mutations than expected. Here, we describe mutations in a second gene
at the EVR1 locus, low-density-lipoprotein receptor–related protein 5 (LRP5), a Wnt coreceptor. This ﬁnding further
underlines the signiﬁcance of Wnt signaling in the vascularization of the eye and highlights the potential dangers
of using multiple families to reﬁne genetic intervals in gene-identiﬁcation studies.
Familial exudative vitreoretinopathy (FEVR [MIM
133780]) is a well-deﬁned inherited disorder of retinal
vessel development (Benson 1995). It is reported to have
a penetrance of 100%, but clinical features can be highly
variable, even within the same family. Severely affected
patients may be legally blind during the 1st decade of
life, whereas mildly affected individuals may not even be
aware of symptoms and may receive a diagnosis only
by use of ﬂuorescein angiography (Ober et al. 1980).
The primary pathological process in FEVR is believed
to be a premature arrest of retinal angiogenesis/vascu-
logenesis or retinal vascular differentiation, leading to
incomplete vascularization of the peripheral retina (van
Nouhuys 1991). This failure to vascularize the periph-
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eral retina is the unifying feature seen in all affected
individuals, but, by itself, it usually causes no clinical
symptoms. The visual problems in FEVR result from
secondary complications due to the development of hy-
perpermeable blood vessels, neovascularization, and vi-
treoretinal traction (ﬁg. 1). These features cause a re-
duction in visual acuity and, in 20% of cases, can lead
to partial or total retinal detachment (van Nouhuys
1991).
FEVR is genetically heterogeneous, with autosomal
dominant (Gow and Oliver 1971; Laqua 1980), X-linked
(Plager et al. 1992; Shastry et al. 1997a), and autosomal
recessive (Shastry and Trese 1997b; De Crecchio et al.
1998) modes of inheritance described, with autosomal
dominant inheritance being the most common (Mu¨ller et
al. 1994; Shastry et al. 2000; Kondo et al. 2001). To date,
two autosomal dominant loci have been mapped. EVR1
on chromosome 11q was the ﬁrst FEVR locus to be iden-
tiﬁed (Li et al. 1992a), and, subsequently, other groups
have published further families with EVR1 linkage (Li et
al. 1992b; Mu¨ller et al. 1994; Price et al. 1996; Shastry
et al. 2000; Kondo et al. 2001), suggesting that mutations
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Figure 1 Clinical appearance of FEVR. Fundus photograph
shows a fold of retinal tissue due to vitreoretinal traction originating
from the temporal periphery. This obscures the posterior pole of the
right eye and therefore compromises the visual acuity.
Figure 2 Schematic diagram of the LRP5 protein showing the location of the mutations within the protein domains. The six YWTD
repeats are shown as a hexagon to represent their b-propeller structure, whereas the EGF domains are represented as gray blocks.
at this locus are a common cause of FEVR. A second
dominant locus, EVR3 on chromosome 11p, has also
been described in a single large pedigree (Downey et al.
2001). Although the gene underlying EVR3 remains un-
identiﬁed, the gene encoding the Wnt receptor frizzled-4,
FZD4 (MIM604579), was recently reported as theEVR1
gene (Robitaille et al. 2002).
Following the identiﬁcation of FZD4 mutations in pa-
tients with FEVR, we screened an FEVR patient panel
of 40 index cases for mutations in this gene. Although
we did ﬁnd mutations, conﬁrming the results of Robi-
taille et al. (2002), these were identiﬁed in only eight
(20%) patients (Toomes et al., in press). A similar low
number of mutations was reported by Robitaille et al.
(2002), who identiﬁed mutations in two (40%) of the
ﬁve families they screened, and a recent study by Kondo
et al. (2003) also identiﬁed mutations in only 5 (20%)
of 24 probands screened. These results are inconsistent
with previous reports suggesting that EVR1 is the com-
mon locus for autosomal dominant FEVR (Mu¨ller et al.
1994; Price et al. 1996; Shastry et al. 2000; Kondo et
al. 2001). Moreover, our screen also revealed the absence
of a mutation in a family with proven EVR1 linkage
(Price et al. 1996). To investigate this family further, we
analyzed the linked haplotype in the EVR1 region of
chromosome 11q13, and we found that crossovers re-
ﬁned the disease gene in this family to an interval of
∼15 cM between the markers D11S1368 and D11S937,
10 cM centromeric to FZD4. These data strongly sug-
gested the presence of a second gene mutated in FEVR,
close to FZD4 and within the previously deﬁned EVR1
locus (Toomes et al. 2004).
Despite the fact that 1250 genes are located within the
deﬁned interval, the discovery that FEVR can be caused
by mutations in the Wnt receptor FZD4 highlighted pro-
teins involved in the Wnt-signaling pathway as candidate
FEVR genes (for an up-to-date list of all the proteins
involved in Wnt signaling, see the Wnt Gene Homepage
maintained by the Roel Nusse lab). We identiﬁed LRP5
(MIM 603506) as one such candidate gene in the region.
LRP5 and its closely related homologue LRP6 encode
single-pass transmembrane receptors that partner with
members of the frizzled family of seven-pass transmem-
brane receptors to bind Wnt proteins, forming a func-
tional ligand-receptor complex that activates the canoni-
cal Wnt-b-catenin pathway (Pinson et al. 2000; Tamai et
al. 2000; Wehrli et al. 2000). LRP5 consists of 23 exons
and encodes a 1,615–amino acid protein. Its extracellular
segment contains four domains, each composed of six
YWTD repeats (which form a b-propeller structure) and
an epidermal growth factor–like domain (YWTD-EGF
domain). These are followed by three low-density-lipo-
protein receptor–like (LDL-R–like) ligand-binding do-
mains (ﬁg. 2). The speciﬁc function of LRP5 remains un-
known, but loss of this protein causes osteoporosis-
pseudoglioma syndrome (OPPG [MIM 259770]), a re-
cessive disorder characterized by very low bone mass and




Exona Primer Name 5′r3′ Sequence Primer Name 5′r3′ Sequence
Size
(bp)
1 A1Fb TTCCGCTCCCGCGCGCCCAGCT 1R2b GCGGGGCCGCCCGGGCCATT 311
2 start 2Fb CATCCCAGGGCTGTGTATCT SSCP 2-R GTGATGACCACGTTCTGCAC 288
2 end SSCP 2-F CAAGCAGACCTACCTGAACC 2Rb ACTTGGGCTCATGCAAATTC 309
3 start 3F3b GAAACCATACCTGTTGGTTATTTCC SSCP 3-R GGATGAAGCTGAGCTTGGCGTC 311
3 end SSCP 3-F CGGATTGAGCGGGCAGGGAT 3R3b CACAGACCCTGACGCTGTTC 323
4 4F4b GATGGCTCCTCCACCCCGCT 4R5b GCGCCCCAGCCGGCACT 250
5 5F3b CTCATTCAGAAACAAGTGACGGTCCTC 5R4b GTCCCGTCCCACCGCCT 216
6 start 6F1b TGGCTGAGTATTTCCCTTGCCC SSCP 6-R GTCGACCGCGATGCCATCGG 352
6 end SSCP 6-F CGACCCGCTAGAGGGCTATGT SSCP 6-2R CAATCTCCCTCTCGCCTGTGC 338
7 7Fb GATGCTGCAGAGACCAGACA 7R2b TAACTATTTTCTCAAGCATTCCATGT 366
8 start 8F1b TGAAGTTGCTGCTCTTGGGCA SSCP 8-R CACCCGCTCGATGCTGCGGC 256
8 end SSCP 8-F CGCACATTTTCGGGTTCACGC 8R1b AACACTTATGCCCAGGCATGGA 252
9 start 9F1b TGCTGGGCTGTTGATGTTTAGACT SSCP 9-R CCGTGAGCGGGATGGCCACG 263
9 end SSCP 9-F GTGCCTGAGGCCTTCTTGGTCT 9R1b CTTGAACTGCGTTACAATAAATACGA 291
10 10F1b GATGCTGGTTCCTAAAATGTGG 10Rb GCTCTAATCACTGAGGGCCA 386
11 11F1b GAGGGCTGAGCTGAAGAGGT 11R1b CAGGTTGGGGAACTTGCAG 398
12 start 12Fb ATTCATGTGGTCGCTAGGCT SSCP 12-R CATCACGAAGTCCAGGTGG 281
12 end SSCP 12-F CTAGCGGCCGGAACCGCA 12Rb GAAGCTCCTTTCAGCGTCAG 287
13 13Fb CCAGCTCCTCTGTGGCTTAC 13Rb TCCTCCCTCTGCTAAGGACA 352
14 SSCP 14-F GTCTCCGCCAGTGCTCAG SSCP 14-R CTGTGAGAGGCTGGCATTC 334
15 SSCP 15-F GTGCTGTCCGAGGAGACGC 15R2b TTACTGACAATGAAGGCCGGGT 305
16 16F1b AAGCTGAGTGTGGGGCAAGTTC SSCP 16-R CCACACAGGATCTTGCACTGG 361
17 17Fb CATGAGTTCTCATTTGGCCC 17Rb GCCACAGGGACTGTGATTTT 321
18 SSCP 18-F GGCTGCGTGTGATGTTCTC 18Rb CAGAGCCCCTACTCCTGTGA 371
19 19Fb CCAGACCTTGGTTGCTGTG 19Rb CGTCTCCTCCCCTAAACTCC 269
20 20NFb ATGTTGGCCACCTCTTTCTG 20NRb CTGCCTCCTCCAGATCATTC 310
21 21Fb GAGTCTCGTGGGTAGTGGGA SSCP 21-R AGAAAGCAAGCATGCCTCAGAG 373
22 S22Fb GGAGGAAGGAAGGAATGCCC 22Rb GCCCACTAGCACCCAGAATA 272
23 SSCP 23-F CGGATGTGCCTACCGAATC SSCP 23-R TTACAGGGGCACAGAGAAGC 347
a Large exons were ampliﬁed in two overlapping segments, designated “start” and “end.”
b Primer sequences obtained from Gong et al. (2001).
prone to developing bone fractures and deformations and
can have various eye abnormalities, including phthisis
bulbi, retinal detachments, falciform folds, or persistent
vitreal vasculature (Frontali et al. 1985). Dominant mis-
sense mutations in LRP5 have also been described in pa-
tients with high-bone-mass disorders (high bone mass
[MIM 601884], endosteal hyperostosis [MIM 144750],
and osteopetrosis [MIM 607634]) (Boyden et al. 2002;
Little et al. 2002; Van Wesenbeeck et al. 2003). It is
thought that these missense mutations result in the for-
mation of a mutant LRP5 protein that is functionally
abnormal (Boyden et al. 2002).
In light of these ﬁndings, LRP5was a strong candidate
for involvement in FEVR and was therefore screened in
the remaining 32 patients from our FEVR patient panel.
Informed consent was obtained from all subjects tested,
and ethical approval was obtained from the Leeds
Teaching Hospitals Trust research ethics committee.
We designed primers (table 1) and screened all 23 exons
and ﬂanking intronic sequences by SSCP-heteroduplex
analysis (SSCP-HA) and direct sequencing, using estab-
lished protocols (Toomes et al. 2001). In total, we dis-
covered six LRP5 mutations not present in control in-
dividuals (ﬁgs. 2 and 3) and a further 13 benign sequence
variants not previously described (table 2).
We ﬁrst identiﬁed a splice-donor mutation that segre-
gated with FEVR in the family with EVR1 linkage in
which FZD4 mutations had been excluded by genetics
(ﬁg. 3B [family 1]). This mutation is a substitution of the
second nucleotide of intron 21, changing the GT splice-
donor site to GG, c44882trg. The precise effect of
this mutation has not been determined in this family,
since no RNA was available. However, the most com-
mon outcome of splice-donor mutations is the deletion
of the preceding exon. This would lead to the deletion
of exon 21, resulting in a frameshift after codon 1449,
followed by 52 incorrect amino acids and a premature
termination at codon 1502.
In a second family originating from the United States,
we identiﬁed a 1-bp insertion in exon 20, c4119-
4120insC. This mutation segregates with the disease in
that family but was also found in two asymptomatic fami-
ly members (ﬁg. 3B [family 2]). However, neither of these




Summary of Novel Benign Sequence Variants Detected in LRP5
Location cDNA Change Protein Change Frequency
Exon 2 324CrG V108V C 98%; G 2%
Intron 2 48853trc … t 52%; c 48%
Exon 3 639CrT D213D C 98%; T 2%
Intron 3 68661crt … c 99%; t 1%
Intron 8 180162 crt … c 99%; t 1%
Intron 11 250337 crt … c 99%; t 1%
Intron 11 250378 gra … g 52%; a 48%
Exon 18 3918GrA A1306A G 99%; A 1%
Intron 20 434813arg … a 99%; g 1%
Exon 21 4380CrT S1460S C 98%; T 2%
Exon 21 4431CrT H1477H C 98%; T 2%
Intron 21 448854cra … c 99%; a 1%
Intron 21 448858gra … g 98%; a 2%
Exon 22 4574TrC V1525A T 99%; C 1%
NOTE.—Amino acid and nucleotide numbering follows the
cDNA sequence, with nucleotide position 1 assigned to the ﬁrst
nucleotide of the ATG initiation codon in exon 1. Bases in exons
are denoted by uppercase letters, bases in introns by lowercase
letters. (NCBI assay ID numbers for these SNPs appear in the
dbSNP entry of the “Electronic-Database Information” section.)
Figure 3 FEVR caused by mutations in LRP5. A, Sequence traces of the six mutations identiﬁed and the corresponding wild-type alleles.
The mutation-sequence trace for exon 18 was obtained from a cloned PCR product, so only the disease allele is shown. Other mutations were
identiﬁed from directly sequenced PCR products and therefore appear as heterozygous changes. B, Mutations segregating in two pedigrees with
FEVR. Unaffected individuals (unblackened); affected individuals (blackened); individuals asymptomatic for FEVR (blackened circle in square).
Family 1 shows the results of a restriction digest assay through use of HphI, the recognition site of which is abolished by the mutation. The
arrow indicates the undigested product present in affected individuals. Family 2 shows an SSCP trace (arrow indicates the aberrant shift). In
family 2, an asterisk (*) indicates individuals affected by low bone mass. C, Protein-sequence alignment of human LRP5 (h) with homologues
from human and other species: Mus musculus (m), X. laevis (x), Drosophila melanogaster (“arrow”), and Anopheles gambiae str. (“mosquito”).
(GenBank accession numbers for all species appear in the “Electronic-Database Information” section.) Only 20 amino acid residues surrounding
each mutation are shown. Conserved amino acid residues are highlighted. The positions of the missense mutations T173M, Y1168H, and
C1361G are indicated. Both Y1168H and C1361G affect highly conserved amino acids, whereas T173M occurs at a less well-conserved residue.
raphy to exclude a very mild phenotype, so their undi-
agnosed condition was not unexpected (Ober et al. 1980).
This mutation causes a frameshift resulting in 175 incor-
rect amino acids after codon 1373, followed by a pre-
mature termination at codon 1549 (K1374fsX1549). The
third mutation identiﬁed was a 1-bp deletion in exon
18, c3804delA, in a single Indian patient. This mutation
causes a frameshift resulting in the substitution of 168
amino acids after codon 1269 and a premature stop in
codon 1438 (R1270fsX1438).
The remaining three potential mutations were missense
changes. In exon 3, we identiﬁed T173M (c518CrT) in
an elderly British woman with abnormal retinal vas-
culature and retinal folds. In exon 16, we identiﬁed
Y1168H (c3502TrC) in a British woman with a total
retinal detachment and retinoschisis. The patient was
born after 36 wk of pregnancy but was never treated
with oxygen therapy. The patient had no family history
of FEVR, although the patient’s asymptomatic father
was also found to have the mutation. The ﬁnal mutation,
C1361G (c4081TrG), was identiﬁed in exon 19 in a 6-
year-old Australian boy with classic features of FEVR.
This patient has very poor vision and has undergone
surgery on his left eye, which is phthisical and sunken.
There is no family history of FEVR, but, again, the
asymptomatic mother was found to have the mutation.
Neither of the asymptomatic parents had been examined
by ﬂuorescein angiography, but they showed no signs of
retinopathy upon fundus examination. To exclude the
possibility that these changes were common polymor-
phisms, we screened 200 ethnically matched control in-
dividuals (400 chromosomes) for each of these changes
(Collins and Schwartz 2002). We also checked each of
the mutated amino acids for conservation within homo-
logues of LRP5 from human and other species (ﬁg. 3C).
Both Y1168H and C1361G are changes to highly con-
served residues. T173M is not well conserved, although
the methionine residue at this position is not seen in any
FZD4 homologue in another species. Whereas these re-
sults suggest that these missense changes are indeed
pathogenic, without further examination by means of a
functional assay, we are unable to prove categorically
that they are disease-causing mutations.
On the basis of these results, we propose that FEVR
results from heterozygous mutations that cause haploin-
sufﬁciency of LRP5. The insertion, deletion, and splicing
mutations all lead to transcripts with premature termi-
nation, which are likely to be targeted by nonsense-me-
diated decay. Similar mutations, when homozygous, cause
OPPG. Indeed, c3804delA has been reported elsewhere
as a homozygous mutation in a patient with OPPG
(Gong et al. 2001). It is therefore likely that the missense
mutations identiﬁed also knock out the function of
LRP5. In support of this theory, the C1361G mutation,
which affects the ﬁfth cysteine within the third LDL-R–
like ligand-binding domain, is an invariant cysteine re-
quired to form a disulﬁde bond necessary for correct
protein folding (Bieri et al. 1995; Fass et al. 1997).
The remaining two missense mutations identiﬁed in
patients with FEVR occur within the ﬁrst and fourth
YWTD-EGF domains (ﬁg. 2). To determine the functional
signiﬁcance of these mutations, we constructed a model
of the YWTD-EGF domain 1 of LRP5 based on the
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Figure 4 Homology model of LRP5 YWTD-EGF domain 1. A, ClustalW alignment of the sequence from the YWTD-EGF domain, from
LDL-R against the four YWTD-EGF domains found in LRP5. Amino acids are numbered in accordance with Swiss-Prot accession number
P01130 (LDL-R) and GenBank accession number NP_002326 (LRP5). The amino acids highlighted in cyan correspond to the location of the
T173M and Y1168H missense changes identiﬁed in the present study. The residues highlighted in pink correspond to the location of the missense
mutations shown elsewhere to cause increased bone density (D111Y, G171V, G171R, A214T, A214V, A242T, and T253I) (Boyden et al. 2002;
Little et al. 2002; Van Wesenbeeck et al. 2003) and OPPG (R570W, R494Q, and V667M) (Gong et al. 2001). The boxes correspond to the
six YWTD-repeats present in the b-propeller module. The LDL-R and model LRP5 domain 1 share 37% sequence identity over 310 residues.
B, Surface representation of the LRP5 YWTD-EGF domain 1. The model is based on the alignment shown in panel A. The location of mutations
listed in panel A are highlighted on the surface in cyan and pink (numbers correspond to the amino acid residues). The blue backbone ribbon
represents the ligand-binding domains R4 and R5 of LDL-R and illustrates how these interact with the propeller domain in LDL-R (Rudenko
et al. 2002). Six of the missense mutations are located on the surface of the LRP5 YWTD-EGF domain 1 structure at a site corresponding to
the protein-protein interface surface between the R4 and R5 ligand-binding domains and the propeller domain of LDL-R. (Figure prepared
using GRASP [Nicholls et al. 1991])
crystal structure of the YWTD-EGF domain of the LDL-
R (Rudenko et al. 2002). To construct the model, the
sequences of the four YWTD-EGF domains of LRP5
were aligned with the LDL-R sequence taken from the
Protein Data Bank entry 1n7d (chain A), through use
of the multiple-sequence-alignment program ClustalW
(Chenna et al. 2003) (ﬁg. 4A). The protein homology-
modeling server Swiss-Model (Schwede et al. 2003) was
then used to construct the model based on this alignment
and the coordinates of the crystal structure of the LDL-
R YWTD-EGF domain (1n7d chain A) (Rudenko et al.
2002) (ﬁg. 4B). We used this model to map the missense
mutations found in this study, as well as those missense
mutations identiﬁed in patients with OPPG and high
bone mass in other studies (Gong et al. 2001; Boyden
et al. 2002; Little et al. 2002; Van Wesenbeeck et al.
2003), onto the three-dimensional structure of the LRP5
protein (ﬁg. 4B).
Many of the mutations occur in the core of the protein
and are likely to cause destabilization of the protein fold.
This includes the FEVR mutation Y1168H from this
study and some of the mutations shown to cause in-
creased bone density (A242T and T253I) and OPPG
(R570W). The remaining mutations occur at the protein
surface (ﬁg. 4B). It is less clear why mutations at these
non–sequence-conserved positions (ﬁg. 3C) would cause
destabilization of the fold. However, six of the eight are
clustered at one location on the protein surface (ﬁg. 4B).
It is interesting that all these mutations (T173M [causing
FEVR] and D111Y, G171V, G171R, A214T, and A214V
[causing high bone density]) are in the YWTD-EGF do-
main 1 of LRP5. Furthermore, all are in the same region
that corresponds to the protein-protein–binding inter-
face between modules R4 and R5 of the ligand-binding
domain of LDL-R and the b-propeller domain of LDL-
R (Rudenko et al. 2002). By analogy with LDL-R, it is
possible that the surface region of the YWTD-EGF do-
mains of LRP5 is also involved in protein-protein inter-
actions and that mutating these nonconserved residues
at the protein surface disrupts functionally important
protein interactions.
Studies of LRP6 suggest that the ﬁrst and second
YWTD-EGF domains are required for LRP6 to interact
functionally with the Wnt-frizzled complex, whereas the
third and fourth YWTD-EGF repeats are required to bind
Dickkopf-1 (Dkk-1), a secreted antagonist of the canoni-
cal Wnt-b-catenin pathway (Mao et al. 2001). A more
recent study in Xenopus has also identiﬁed a new LRP6-
interacting protein known as “Wise.” Depending on its
environment, Wise can act as both an activator and an
inhibitor of Wnt signaling and interacts with the ﬁrst
and second YWTD-EGF repeats of LRP6, presumably
by competing with the Wnt-frizzled complex (Itasaki et
al. 2003). The high similarity between LRP5 and LRP6
suggests that equivalent interactions will occur in LRP5.
Consistent with this notion, LRP5 has been shown to
interact with different Wnt/frizzled complexes (Tamai et
al. 2000; Seme¨nov et al. 2001; Kato et al. 2002; Cari-
casole et al. 2003), although the binding sites have not
been determined. Similarly, LRP5 has been shown to
interact with Dkk-1 (Baﬁco et al. 2001; Caricasole et al.
2003), and in vitro studies have shown that the antag-
onizing effect of Dkk-1 on Wnt signaling is almost abol-
ished when the wild-type LRP5 protein is replaced with
one harboring the G171Vmutation known to cause high
bone mass (Boyden et al. 2002). Furthermore, LRP5 has
also been reported to interact with other members of the
Dickkopf (Dkk) family of proteins, Dkk-2 and Dkk-3
(Caricasole et al. 2003), and evidence suggests that these
proteins, like the Wise protein, can function as either
agonists or antagonists, depending on their cellular con-
text (Wu et al. 2000; Mao and Niehrs 2003). These
preliminary experiments indicate that comparable re-
sults can be obtained for both LRP5 and LRP6 and
strengthen the conclusions, based on the modeling data,
that the missense mutations disrupt a protein-binding
site.
Expression studies have shown that LRP5 and LRP6
are widely expressed in both embryonic and adult tis-
sues, including the retina (Brown et al. 1998; Hey et al.
1998; Kim et al. 1998). However, whereas mice lacking
Lrp6 show a wide range of developmental defects in
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multiple organs (Pinson et al. 2000), mice lacking Lrp5
have a restricted phenotype. Two groups have indepen-
dently created mice with a targeted disruption of Lrp5
(Kato et al. 2002; Fujino et al. 2003), but it is surprising
that these mice had different phenotypes. Kato et al.
(2002) disrupted Lrp5 at amino acid 373 (exon 6), and
immunohistochemistry showed that this allele resulted
in the formation of a truncated polypeptide. The resul-
tant homozygous mice had low bone mass and persistent
embryonic eye vascularization, a phenotype similar to
that observed in patients with OPPG. Fujino et al. (2003)
disrupted Lrp5 at exon 18, but, this time, both immuno-
blotting and northern analysis indicated that the homo-
zygous mice totally lacked Lrp5. These mice appeared
normal, with no eye phenotype documented and only a
very mild low-bone-mass phenotype, similar to osteo-
porosis, present in females aged 16 mo. These mice were,
however, shown to have defects in their cholesterol me-
tabolism and glucose-induced insulin secretion (Fujino
et al. 2003). In both studies, the eyes of the heterozygotes
appeared normal, but detailed analysis of the retinal vas-
culature by ﬂuorescein angiography was not reported,
so an FEVR phenotype cannot be ruled out.
In light of the results of the present study, we would
have expected obligate OPPG carriers to have FEVR; it
is surprising, therefore, that no eye defects have been re-
ported. This is presumably a result of the subtle pheno-
type observed in some patients with FEVR (Ober et al.
1980). OPPG carriers have, however, been found to have
reduced bone mass, when compared with age- and sex-
matched control individuals (Gong et al. 2001). A closer
inspection of affected members of family 2 who had the
c4119–4120insC mutation showed that they, too, had
signs of low bone mass (ﬁg. 3B). Individual I:2 is os-
teoporotic. Her bone mineral density (BMD) is 60% of
the normal sex-matched value and 65% of the age- and
sex-matched value. No BMD ﬁgures were available for
other affected family members, but their medical his-
tories highlighted a large number of fractures. Individ-
uals III:2 and III:3 have had multiple radius and humerus
bone fractures since age 6 mo. Individual III:4 had a
radial bone fracture at age 5 years, and individual I:3
has had six breaks in total (left wrist, right wrist, foot,
femur, clavicle in two places, and right arm). These re-
sults suggest that patients with FEVR who have LRP5
mutations show signs of osteoporosis, a clinical feature
not previously noted in FEVR.
The microheterogeneity observed in this study high-
lights potential dangers in using multiple families for
disease-gene reﬁnement and identiﬁcation. It is possible
that one or both of these neighboring FEVR genes could
have been excluded by combining haplotype data from
families with mutations in both FZD4 and LRP5, a wor-
rying scenario for disease gene–mapping projects. Like-
wise, if the genetic analysis in family 1 had not excluded
FZD4 as the mutated gene in the family, the search for
their mutation would have been abandoned, since it
would have been presumed to lie outside the coding
sequence of the gene. As a result, the second mutated
gene at this locus might not have been identiﬁed.
In summary, we have shown that mutations in either
LRP5 or FZD4, two distinct genes within the EVR1
locus, can cause FEVR. Together, these two loci account
for 35% of FEVR cases in our patient series (15% LRP5
and 20% FZD4), indicating that other unidentiﬁed FEVR
genes may be a more signiﬁcant cause of the disease than
previously thought. The primary pathological process in
FEVR is believed to be a premature arrest of retinal
angiogenesis/vasculogenesis or retinal vascular differ-
entiation, leading to incomplete vascularization of the
peripheral retina. The implication of two components
of the Wnt-signaling pathway in this disease process
highlights the importance of its role in the development
of the vasculature of the eye and, potentially, other
organs.
Acknowledgments
We thank the families with FEVR, for their help in this study;
The Wellcome Trust, for grants 069718/Z/02, 055145/Z/98,
and 035535/Z/96; and the Jack Brockhoff Foundation, for
ﬁnancial support. K.Z. is supported by National Institutes of
Health grants RO1EY14438, RO1EY14448, and GCRC M01-
RR00064; the American Health Assistance Foundation; the
Ruth and Milton Steinbach Fund; and the Ronald McDonald
House Charities.
Electronic-Database Information
Accession numbers and URLs for data presented herein are
as follows:
ClustalW, http://www.ebi.ac.uk/clustalw/
dbSNP, http://www.ncbi.nlm.nih.gov/SNP/ (for NCBI assay
IDs ss16359666, ss16359667, ss16359668, ss16359669,
ss16359670, ss16359671, ss16359672, ss16359673,
ss16359674, ss16359675, ss16359676, ss16359677,
ss16359678, and ss16359679)
GenBank, http://www.ncbi.nlm.nih.gov/Genbank/ (for hLRP5
[accession numbers NP_002326 and NM_002335], mLRP5
[accession number NP_032539], xLRP5 [accession number
AAN09806], hLRP6 [accession number NP_002327],
mLRP6 [accession number NP_032540] xLRP6 [accession
number AAN09807], arrow [accession number AAF91072],
mosquito [accession number EAA00402], and hLRP4 [ac-
cession number XP_035037])
Online Mendelian Inheritance in Man (OMIM), http://www
.ncbi.nlm.nih.gov/Omim/ (for FEVR, FZD4, LRP5, OPPG,
high bone mass, endosteal hyperostosis, and osteopetrosis)
Protein Data Bank, http://www.rcsb.org/pdb/
Swiss-Model, http://swissmodel.expasy.org/
Reports 729
Swiss-Prot, http://ca.expasy.org/sprot/sprot-top.html (for LDL-
R [accession number P01130])
Wnt Gene Homepage, http://www.stanford.edu/˜rnusse/
wntwindow.html
References
Baﬁco A, Liu G, Yaniv A, Gazit A, Aaronson SA (2001) Novel
mechanisms of Wnt signalling inhibition mediated by Dick-
kopf-1 interaction with LRP6/arrow. Nat Cell Biol 3:683–
686
Benson WE (1995) Familial exudative vitreoretinopathy. Trans
Am Ophthalmol Soc 93:473–521
Bieri S, Djordjevic JT, Daly NL, Smith R, Kroon PA (1995)
Disulﬁde bridges of a cysteine-rich repeat of the LDL receptor
ligand-binding domain. Biochemistry 34:13059–13065
Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA,
Wu D, Insogna K, Lifton RP (2002) High bone density due
to a mutation in LDL-receptor-related protein 5. N Engl J
Med 346:1513–1521
Brown SD, Twells RCJ, Hey PJ, Cox RD, Levy ER, Soderman
AR, Metzker ML, Caskey CT, Todd JA, Hess JF (1998)
Isolation and characterization of LRP6, a novel member of
the low density lipoprotein receptor gene family. Biochem
Biophys Res Commun 248:879–888
Caricasole A, Ferraro T, Iacovelli L, Barletta E, Caruso A, Mel-
chiorri D, Terstappen GC, Nicoletti F (2003) Functional
characterization of WNT7A signalling in PC12 cells. J Biol
Chem 278:37024–37031
Chenna R, Sugawara H, Koike T, Lopez R, Gibson TJ, Higgins
DG, Thompson JD (2003)Multiple sequence alignmentwith
the Clustal series of programs. Nucleic Acids Res 31:3497–
3500
Collins JS, Schwartz CE (2002) Detecting polymorphisms and
mutations in candidate genes. Am J Hum Genet 71:1251–
1252
De Crecchio G, Simonelli F, Nunziata G, Mazzeo S, Greco GM,
Rinaldi E, Ventruto V, Ciccodicola A, Miano MG, Testa F,
Curci A, D’Urso M, Rinaldi MM, Cavaliere ML, Castel-
luccio P (1998) Autosomal recessive familial exudative vi-
treoretinopathy: evidence for genetic heterogeneity. Clin Ge-
net 54:315–320
Downey LM, Keen TJ, Roberts E, Mansﬁeld DC, Bamashmus
M, Inglehearn CF (2001) A new locus for autosomal domi-
nant familial exudative vitreoretinopathy maps to chromo-
some 11p12-13. Am J Hum Genet 68:778–781
Fass D, Blacklow S, Kim PS, Berger JM (1997)Molecular basis
of familial hypercholesterolaemia from structure of LDL re-
ceptor module. Nature 388:691–693
Frontali M, Stomeo C, Dallapiccola (1985)Osteoporosis-pseu-
doglioma syndrome: report of three affected sibs and an over-
view. Am J Med Genet 22:35–47
Fujino T, Asaba H, Kang M-J, Ikeda Y, Sone H, Takada S,
Kim D-H, Ioka RX, Ono M, Tomoyori H, Okubo M, Mu-
rase T, Kamataki A, Yamamoto J, Magoori K, Takahashi S,
Miyamoto Y, Oishi H, Nose M, Okazaki M, Usui S, Imai-
zumi K, YanagisawaM, Sakai J, Yamamoto TT (2003) Low-
density lipoprotein receptor-related protein 5 (LRP5) is es-
sential for normal cholesterol metabolism and glucose-in-
duced insulin secretion. Proc Natl Acad Sci USA 100:229–
234
Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Re-
ginato AM, Wang H, et al (2001) LDL receptor-related pro-
tein 5 (LRP5) affects bone accrual and eye development.
Cell 107:513–523
Gow J, Oliver GL (1971) Familial exudative vitreoretinopathy:
an expanded view. Arch Ophthalmol 86:150–155
Hey PJ, Twells RCJ, Phillips MS, Nakagawa Y, Brown SD,
Kawaguchi Y, Cox R, Xie G, Dugan V, Hammond H, Metz-
kerML, Todd JA, Hess JF (1998) Cloning of a novel member
of the low-density lipoprotein receptor family. Gene 216:
103–111
Itasaki N, Jones CM, Mercurio S, Rowe A, Domingos PM,
Smith JC, Krumlauf R (2003) Wise, a context-dependent
activator and inhibitor of Wnt signalling. Development 130:
4295–4305
Kato M, Patel MS, Levasseur R, Lobov I, Chang BH-J, Glass
DA, Hartmann C, Li L, Hwang T-H, Brayton CF, Lang RA,
Karsenty G, Chan L (2002) Cbfa1-independent decrease in
osteoblast proliferation, osteopenia, and persistent embryonic
eye vascularization in mice deﬁcient in Lrp5, a Wnt core-
ceptor. J Cell Biol 157:303–314
Kim D-H, Inagaki Y, Suzuki T, Ioka RX, Yoshioka SZ, Ma-
goori K, Kang M-J, Cho Y, Nakano AZ, Liu Q, Fujino T,
Suzuki H, Sasano H, Yamamoto TT (1998) A new low den-
sity lipoprotein receptor related protein, LRP5, is expressed
in hepatocytes and adrenal cortex, and recognizes apolipro-
tein E. J Biochem 124:1072–1076
Kondo H, Hayashi H, Oshima K, Tahira T, Hayashi K (2003)
Frizzled 4 gene (FZD4) mutations in patients with familial
exudative vitreoretinopathy with variable expressivity. Br J
Ophthalmol 87:1291–1295
Kondo H, Ohno K, Tahira T, Hayashi H, Oshima K, Hayashi
K (2001) Delineation of the critical interval for the familial
exudative vitreoretinopathy gene by linkage and haplotype
analysis. Hum Genet 108:368–375
Laqua H (1980) Familial exudative vitreoretinopathy. Albrecht
Von Graefes Arch Klin Exp Ophthalmol 213:121–133
Li Y, Fuhrmann C, Schwinger E, Gal A, Laqua H (1992a) The
gene for autosomal dominant exudative vitreoretinopathy
(Criswick-Schepens) on the long arm of chromosome 11. Am
J Ophthalmol 113:712–713
Li Y, Mu¨ller B, Fuhrmann C, van Nouhuys CE, Laqua H,
Humphries P, Schwinger E, Gal A (1992b) The autosomal
dominant familial exudative vitreoretinopathy locus maps
on 11q and is closely linked to D11S533. Am J Hum Genet
51:749–754
Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M,
Folz C, Manning SP, et al (2002) A mutation in the LDL
receptor–related protein 5 gene results in the autosomal domi-
nant high–bone-mass trait. Am J Hum Genet 70:11–19
Mao B, Niehrs, C (2003) Kremen2 modulates Dickkopf2 ac-
tivity during Wnt/LRP6 signalling. Gene 302:179–183
Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C
(2001) LDL-receptor-related protein 6 is a receptor for Dick-
kopf proteins. Nature 411:321–325
Mu¨ller B, Orth U, van Nouhuys CE, Duvigneau C, Fuhrmann
C, Schwinger E, Laqua H, Gal A (1994) Mapping of the
autosomal dominant exudative vitreoretinopathy locus
730 Am. J. Hum. Genet. 74:721–730, 2004
(EVR1) by multipoint linkage analysis in four families. Gen-
omics 20:317–319
Nicholls A, Sharp KA, Honig B (1991) Protein folding and
association: insights from the interfacial and thermodynamic
properties of hydrocarbons. Proteins 11:281–296
Ober RR, Bird AC, Hamilton AM, Sehmi K (1980) Autosomal
dominant exudative vitreoretinopathy. Br J Ophthalmol 64:
112–120
Pinson KI, Brennan J, Monkley S, Avery BJ, Skames WC (2000)
An LDL receptor-related protein mediates Wnt signalling in
mice. Nature 407:535–538
Plager DA, Orgel IK, Ellis FD, Hartzer M, Trese MT, Shastry
BS (1992) X-linked recessive familial exudative vitreoretin-
opathy. Am J Ophthalmol 114:145–148
Price SM, Periam N, Humphries A, Woodruff G, Trembath
RC (1996) Familial exudative vitreoretinopathy linked to
D11S533 in a large Asian family with consanguinity. Oph-
thalmic Genet 17:53–57
Robitaille J, MacDonaldMLE, Kaykas A, Sheldahi LC, Zeisler
J, Dube MP, Zhang LH, Singaraja RR, Guernsey DL, Zheng
B, Siebert LF, Hoskin-Mott A, TreseMT, Pimstone SN, Shas-
try BS, Moon RT, Hayden MR, Goldberg YP, Samuels ME
(2002) Mutant frizzled-4 disrupts retinal angiogenesis in fa-
milial exudative vitreoretinopathy. Nat Genet 32:326–330
Rudenko G, Henry L, Henderson K, Ichtchenko K, Brown MS,
Goldstein JL, Deisenhofer J (2002) Structure of the LDL re-
ceptor extracellular domain at endosomal pH. Science 298:
2353–2358
Schwede T, Kopp J, Guex N, Peitsch MC (2003) SWISS-
MODEL: an automated protein homology-modelling server.
Nucleic Acids Res 31:3381–3385
Seme¨novMV, Tamai K, Brott BK, Ku¨hlM, Sokol S, HeX (2001)
Head inducer Dickkopf-1 is a ligand for Wnt coreceptor
LRP6. Curr Biol 11:951–961
Shastry BS, Hejtmancik JF, Hiraoka M, Ibaraki N, Okubo Y,
Okubo A, Han DP, Trese MT (2000) Linkage and candidate
gene analysis of autosomal-dominant familial exudative vi-
treoretinopathy. Clin Genet 58:329–332
Shastry BS, Liu X, Hejtmancik JF, Plager DA, TreseMT (1997a)
Evidence for genetic heterogeneity in X-linked familial exu-
dative vitreoretinopathy. Genomics 44:247–248
Shastry BS, Trese MT (1997b) Familial exudative vitreoretin-
opathy: further evidence for genetic heterogeneity. Am JMed
Genet 69:217–218
Tamai K, Semenov M, Kato Y, Spokony R, Liu C, Katsuyama
Y, Hess F, Saint-Jeannet JP, He X (2000) LDL-receptor-re-
lated proteins in Wnt signal transduction. Nature 407:530–
535
Toomes C, Bottomley HM, Scott S, Mackey DA, Craig JE,
Appukuttan B, Stout JT, Zhang K, Black GCM, Fryer A,
Downey LM, Inglehearn CF. Spectrum and frequency of
FZD4 mutations in familial exudative vitreoretinopathy
(FEVR). Invest Ophthalmol Vis Sci (in press)
Toomes C, Downey LM, Bottomley HM, Scott S, Woodruff
G, Trembath RC, Inglehearn CF (2004) Identiﬁcation of a
fourth locus (EVR4) for familial exudative vitreoretinopathy
(FEVR). Mol Vis 10:37–42
Toomes C, Marchbank NJ, Mackey DA, Craig, JE, Newbury-
Ecob, RA, Bennett, CP, Vize, CJ, Desai, SP, Black, GCM,
Patel, N, Teimory, M, Markham, AF, Inglehearn, CF, Chur-
chill, AJ (2001) Spectrum, frequency and penetrance ofOPA1
mutations in dominant optic atrophy. Hum Mol Genet 10:
1369–1378
van Nouhuys CE (1991) Signs, complications, and platelet
aggregation in familial exudative vitreoretinopathy. Am J
Ophthalmol 111:34–41
Van Wesenbeeck L, Cleiren E, Gram J, Beals RK, Be´nichou O,
Scopelliti D, Key L, Renton T, Bartels C, Gong Y, Warman
ML, de Vernejoul M-C, Bollerslev J, Van Hul W (2003) Six
novel missense mutations in the LDL receptor-related pro-
tein 5 (LRP5) gene in different conditions with an increased
bone density. Am J Hum Genet 72:763–771
Wehrli M, Dougan ST, Caldwell K, O’Keefe L, Schwartz S,
Vaizel-Ohayon D, Schejter E, Tomlinson A,DiNardo S (2000)
Arrow encodes an LDL-receptor-related protein essential for
Wingless signalling. Nature 407:527–530
Wu W, Glinka A, Delius H, Niehrs, C (2000) Mutual antag-
onism between Dickkopf1 and Dickkopf2 regulates Wnt/b-
catenin signalling. Curr Biol 10:1611–1614
